Kalaris Therapeutics (KLRS) Accumulated Expenses (2019 - 2020)
Kalaris Therapeutics (KLRS) has 2 years of Accumulated Expenses data on record, last reported at $7.8 million in Q3 2020.
- For Q3 2020, Accumulated Expenses changed N/A year-over-year to $7.8 million; the TTM value through Sep 2020 reached $7.8 million, changed N/A, while the annual FY2019 figure was $5.2 million, N/A changed from the prior year.
- Accumulated Expenses reached $7.8 million in Q3 2020 per KLRS's latest filing, up from $2.8 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $7.8 million in Q3 2020 and bottomed at $2.8 million in Q2 2020.